BCL2 and lymphoma: These included one 81-year-old patient in PR after three cycles of treatment with venetoclax (Figure 1) that converted to CR at cycle 9 and was maintained 24 months from the beginning of treatment; this patient had PTCL-NOS histology with 50% BCL2 lymphoma cell positivity.